The Medicines and Healthcare products Regulatory Agency (MHRA) updated its register of orphan medicinal products on 15 April 2026, reflecting the growing number of treatments authorised for rare diseases in the UK. For community pharmacists, orphan medicines represent an increasingly visible — if still uncommon — category of dispensing that demands specific knowledge and care.

What is an orphan medicine?

An orphan medicine is a pharmaceutical product developed to treat a rare condition — defined in UK regulation as one affecting fewer than 5 in 10,000 people. Orphan designation provides regulatory incentives (reduced fees, protocol assistance, market exclusivity) to encourage development of treatments that would otherwise be commercially unviable.

The MHRA maintains a public register of all medicines granted orphan designation and subsequently authorised for the UK market. This list has grown steadily as gene therapies, enzyme replacement therapies and targeted small molecules have expanded the treatment landscape for conditions that were previously untreatable.

Why this matters for community pharmacy

While most orphan medicines are initiated and monitored in specialist centres, community pharmacists may encounter them in several scenarios:

Ongoing supply: Patients stabilised on orphan medicines who collect repeat prescriptions from their local pharmacy. Examples include miglustat (Zavesca) for Gaucher disease, bosentan (Tracleer) for pulmonary arterial hypertension, and deferasirox (Exjade) for iron overload in transfusion-dependent patients.

Shared care arrangements: Some orphan medicines are prescribed under shared care protocols where the GP takes over prescribing from the specialist centre, and the community pharmacy dispenses. The pharmacist must understand the monitoring requirements specified in the shared care agreement.

Homecare medication: Patients receiving parenteral orphan medicines (such as enzyme replacement therapies) via homecare providers may ask their community pharmacist questions about their treatment, side effects or interactions with other medicines.

Dispensing considerations

Orphan medicines present several practical challenges:

Stock availability: Most orphan medicines are not routinely stocked by community pharmacies. Ordering may require direct arrangements with specialist wholesalers or the manufacturer. Lead times can be longer than for standard lines. Pharmacists should plan ahead and ensure the patient is never left without supply due to ordering delays.

Cold chain requirements: Many orphan medicines — particularly biologics and enzyme replacement therapies — require cold chain storage (2–8°C). Pharmacists must verify their cold chain capacity and temperature monitoring is adequate before agreeing to hold stock.

Cost: Individual orphan medicines can cost tens of thousands of pounds per year. While the NHS bears the cost, pharmacists should be aware of the reimbursement pathway and any endorsement requirements to ensure payment is not delayed.

Patient information: Patients on orphan medicines often know more about their condition than most healthcare professionals they encounter. Pharmacists should respect this expertise while still performing standard clinical checks — interactions, allergies, dose verification. The patient's specialist team contact details should be on file for any queries.

Interactions and clinical checks

Orphan medicines are often metabolised via CYP450 pathways and may have significant interactions with commonly prescribed medicines. Examples:

Pharmacists should check the Summary of Product Characteristics (SmPC) for any orphan medicine they have not dispensed before. The Electronic Medicines Compendium (emc.medicines.org.uk) is the authoritative UK source.

Supporting patients with rare diseases

Living with a rare disease can be isolating. Many patients travel long distances for specialist appointments, face diagnostic delays averaging 5 years (according to Rare Disease UK), and encounter healthcare professionals unfamiliar with their condition.

Community pharmacists can support these patients by:

• Learning the basics of the patient's condition — a 5-minute read of the relevant orphan medicine SmPC and the patient charity's information page
• Ensuring continuity — the same pharmacist handling each dispensing interaction, where possible
• Proactive ordering — anticipating repeat supply dates rather than waiting for the patient to request
• Signposting to patient organisations such as Genetic Alliance UK, Rare Disease UK, and condition-specific charities
• Recording the specialist centre and key contact in the patient's pharmacy record

The England Rare Diseases Action Plan, updated in 2026, explicitly identifies community pharmacists as part of the care pathway for rare disease patients — recognising that pharmacy is often the most accessible healthcare setting between specialist appointments.

Yellow Card reporting

Adverse drug reaction (ADR) reporting is particularly important for orphan medicines, where post-marketing data is often limited by the small patient population. Pharmacists should encourage patients to report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) and should submit professional reports for any clinically significant reactions they observe.

Training and development

Pharmacists interested in rare disease pharmacy can access resources through:

• The Centre for Pharmacy Postgraduate Education (CPPE) specialist modules
• The Royal Pharmaceutical Society's guidance on specialist medicines
• The UK Clinical Pharmacy Association's special interest groups
• Hospital pharmacy rotations in metabolic medicine, haematology and respiratory — where most orphan medicine prescribing is concentrated

The PharmSee job board lists vacancies in specialist hospital pharmacy roles where orphan medicine expertise is valued. Salary data for these roles is available in the PharmSee salary guide, and the pharmacy finder helps patients locate their nearest dispensing pharmacy.

Sources: MHRA register of orphan registered medicinal products (updated 15 April 2026); Orphan Medicinal Products Regulation (as retained in UK law); England Rare Diseases Action Plan 2026; NICE Technology Appraisals for listed medicines; Electronic Medicines Compendium SmPCs (accessed April 2026); Rare Disease UK diagnostic odyssey report.